BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CardioFocus Inc. HeartLight® EAS Symposium Features Two Years of Clinical Experience at German Society of Cardiology Annual Meeting


4/26/2012 11:18:38 AM

MARLBOROUGH, Mass., April 26, 2012 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), convened cardiology thought leaders to discuss clinical experiences with its technology and identify areas for continued research during a sponsored symposium at the German Society of Cardiology Annual Meeting in Mannheim, Germany, April 11-14. Presenters highlighted the versatility and durability of endoscopic laser catheter ablation, and addressed topics related to the unique energy delivery mechanism and its applicability in a range of patient anatomies.

The program, "Two years of laser ablation with the endoscope: First results and outlook," was chaired by Prof. Thorsten Lewalter, MD, of Isar Heart Center Munich, Germany, and Boris Schmidt, MD, of Cardioangiologisches Centrum Bethanien, Frankfurt, Germany. It featured presentations ranging from single center experiences to a worldwide, multicenter 400 patient experience with the HeartLight EAS, the first catheter ablation system to feature an endoscope for direct visualization of the beating heart. The system also incorporates a compliant, dynamically adjustable balloon catheter for improved contact with the pulmonary vein (PV) ostium and unique laser energy source for more efficient, precise ablation.

"The symposium featured notable acute and long-term data on the ease of use and PV isolation enabled by the HeartLight EAS, further supporting the value of integrating the system into clinical practice," said Dr. Schmidt. "With over two years of experience with the technology in Germany and documented successful patient outcomes, the system has become an established AF treatment option at many centers. We look forward to continuing to delve deeper into the applicability of the system and the nuances of laser energy delivery."

In one presentation, Erik Wissner, MD, of Asklepios Klinik St. Georg, Hamburg, Germany, further explored the impact of variables including patient selection and energy titration on acute PV isolation with the HeartLight EAS. His research demonstrated a high rate of acute PV isolation (192/195), irrespective of individual patient anatomy, with no correlation between isolation gap location and PV anatomy. Additionally, he noted first-of-its kind data suggest the system can achieve up to 90% isolation (36/40) after a single circumferential lesion set when using a higher energy level (8.5/10W), while maintaining a similar safety profile to lower energy ablation.

"Our clinical experiences suggest the HeartLight EAS is a highly adaptable system that can be widely used to treat patients with paroxysmal AF, at varied energy levels and independent of individual anatomy, enabling greater intra-operative versatility," said Dr. Wissner. "Further, we've achieved these results while maintaining the low complication rate and high single procedure efficacy that have come to be associated with HeartLight EAS ablation. We will continue to explore the potential of the technology to deliver complete PV isolation with a single lesion set, with energy levels that remain lower than that of alternative systems."

For more information on HeartLight EAS, please visit www.CardioFocus.com.

About CardioFocus, Inc.

CardioFocus, Inc. is a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF). Its novel HeartLight® Endoscopic Ablation System for catheter ablation incorporates an endoscope to provide physicians with the capacity to see within the heart, and for the first time, visually direct the application of laser energy to achieve durable pulmonary vein isolation.

The HeartLight Endoscopic Ablation System is commercially available at leading institutions throughout Europe. The device is investigational in the U.S., and currently the focus of a pivotal trial initiated in 2012. CardioFocus is headquartered in Marlborough, MA, USA. For more information on the company and its technology, please visit www.CardioFocus.com.

The scientific information discussed in this news release is preliminary and investigative. The CardioFocus HeartLight Endoscopic Ablation System is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the system. Only FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Healthcare professionals should refer to/rely upon FDA-approved labeling for the products, and not the information discussed in this news release.

Company Contact:

Media Contact:

Anjie Roldan

Lisa Cook

Vice President Finance

(646) 536-7012

(508) 658-7237

lcook@theruthgroup.com

aroldan@cardiofocus.com


SOURCE CardioFocus, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES